C

Corvus Pharmaceuticals
D

CRVS

3.50000
USD
0.02
(0.57%)
مغلق
حجم التداول
9,211
الربح لكل سهم
-0
العائد الربحي
-
P/E
-3
حجم السوق
269,901,226
أصول ذات صلة
A
ALT
-0.05500
(-0.95%)
5.71000 USD
A
AYTU
-0.07000
(-3.43%)
1.97000 USD
MRNA
MRNA
-0.820
(-3.03%)
26.280 USD
N
NNVC
0.29500
(19.87%)
1.78000 USD
N
NVAX
-0.04000
(-0.55%)
7.25000 USD
R
RFL
-0.00500
(-0.37%)
1.34000 USD
V
VCEL
-0.440
(-1.06%)
40.970 USD
V
VXRT
-0.00260
(-0.56%)
0.46340 USD
المزيد
الأخبار المقالات

العنوان: Corvus Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).